Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a session volume of 14.32 million versus the average volume of 118.9K as per data from Benzinga Pro. The company received substantial additional orders for TrinScreen HIV. Due to this demand and the scaling of production capacity, the company is now increasing its expected 2024 sales revenue for TrinScreen HIV to approximately $10 million, up from $8 million. President and Chief Executive Officer of Trinity Biotech, John Gil
The company reported about $4.4 billion in profits in the quarter, a 144% increase compared to last year — but the CEO said such profits won't last.
(Bloomberg) -- With Nvidia Corp. earnings just a day away and a heavy slate of US economic data scheduled for later in the week, there was little movement in markets on Tuesday.Most Read from BloombergNazi Bunker’s Leafy Makeover Turns Ugly Past Into Urban EyecatcherSydney Central Train Station Is Now an Architectural DestinationChicago Overcomes DNC Skeptics With Calm, Parties and SunHow the Cortiços of São Paulo Helped Shelter South America’s Largest CityWith Housing Costs High, Democrats Hone
Five Below is one of this year's biggest losers, but it has a telltale financial update coming soon.
This energy stock is focused on generating strong free cash flow and returning it to investors.
(Bloomberg) -- The topsy-turvy US presidential election has Wall Street racing to adjust its bets as Democratic party candidate Vice President Kamala Harris keeps surging in the polls against the once presumptive favorite, Republican former President Donald Trump.Most Read from BloombergNazi Bunker’s Leafy Makeover Turns Ugly Past Into Urban EyecatcherSydney Central Train Station Is Now an Architectural DestinationChicago Overcomes DNC Skeptics With Calm, Parties and SunHow the Cortiços of São P
Pfizer is launching a new direct-to-consumer platform that it hopes will help patients get access to medicines faster.
